Previous 10 | Next 10 |
2023-07-03 10:02:15 ET Summary This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will re...
2023-07-03 06:49:30 ET Summary We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic...
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Treat Duchenne Muscular Dystrophy Catalyst Exp...
2023-06-01 12:09:13 ET Catalyst Pharmaceuticals ( NASDAQ: CPRX ) reaffirmed its full-year 2023 total revenue and products outlook. The company continues to expect FY23 revenue to be between $375M and $385M, growing 75% to 80% Y/Y (consensus $381.28M). Catalyst also reaffirme...
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Appr...
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare dise...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
2023-05-22 08:15:00 ET In the last 30 days, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. As you might be guessing, the culprit for the tumble was the company's abysma...
2023-05-11 11:51:08 ET Catalyst Pharmaceuticals Inc. (CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 am ET Company Participants Patrick McEnany - Chairman, Chief Executive Officer Alicia Grande - Vice President, Chief Financial Officer Jeff Del Carmen -...
2023-05-10 16:38:30 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q1 Non-GAAP EPS of $0.41 beats by $0.10 . Revenue of $85.4M (+98.2% Y/Y) beats by $3.78M . Cash and equivalents were $148.2 Million as of March 31, 2023. Affirms Full Year Tot...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...